Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 5/20 | 0.36 |
| ▸ | HTR2B | P41595 | 4/20 | 0.36 |
| ▸ | HTR2A | P28223 | 4/20 | 0.36 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.36 |
| ▸ | GRM5 | P41594 | 1/20 | 0.33 |
| ▸ | RBP4 | P02753 | 1/20 | 0.32 |
| ▸ | MGLL | Q99685 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | JAK2 | O60674 | 1/20 | 0.31 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.31 |
| ▸ | NTRK3 | Q16288 | 2/20 | 0.31 |
| ▸ | NTRK2 | Q16620 | 2/20 | 0.31 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21231884 | 0.91 | HTR2C (0.34) | HTR2CHTR2BHTR2AIRAK4GRM5 | |
| SCHEMBL18907020 | 0.89 | HTR2A (0.36) | HTR2CHTR2BHTR2AIRAK4GRM5 | |
| SCHEMBL18907906 | 0.83 | HTR2A (0.41) | HTR2CHTR2BHTR2AIRAK4GRM5 | |
| SCHEMBL18909751 | 0.76 | KDM4E (0.39) | HTR2CHTR2A | |
| SCHEMBL18908169 | 0.76 | KCNH2 (0.39) | HTR2CHTR2BHTR2AKMT2A | |
| SCHEMBL18908181 | 0.76 | L3MBTL1 (0.36) | HTR2CHTR2BHTR2AJAK2 | |
| SCHEMBL18907926 | 0.74 | ALDH1A1 (0.45) | HTR2CHTR2BHTR2AGRM5RBP4 | |
| SCHEMBL17111325 | 0.74 | DRD4 (0.46) | HTR2CHTR2BHTR2AFFAR1 | |
| SCHEMBL22479944 | 0.71 | HTR2A (0.50) | HTR2CHTR2BHTR2ARBP4 | |
| SCHEMBL31710828 | 0.71 | PKM (0.49) | HTR2CHTR2BHTR2AGRM5RBP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170166584-A1 | TRIAZOLE ACC INHIBITORS AND USES THEREOF | Nimbus Apollo, Inc. | 2017-06-15 | — | — | US | disclosed |
| WO-2017091617-A1 | TRIAZOLE ACC INHIBITORS AND USES THEREOF | GILEAD APOLLO, LLC (US) | 2017-06-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170166584-A1 | TRIAZOLE ACC INHIBITORS AND USES THEREOF | ACACA, ACACB, ACAT1 | HTR2C 4420/4885HTR2B 4786/4885HTR2A 4785/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.